


## Palmatine

<b>Cat. No.:</b>	HY-N0110A
<b>CAS No.:</b>	3486-67-7
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>22</sub> NO <sub>4</sub> <sup>+</sup>
<b>Molecular Weight:</b>	352.4
<b>Target:</b>	Indoleamine 2,3-Dioxygenase (IDO); Apoptosis; Virus Protease; Aurora Kinase; Bacterial; Parasite; mAChR
<b>Pathway:</b>	Metabolic Enzyme/Protease; Apoptosis; Anti-infection; Cell Cycle/DNA Damage; Epigenetics; GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### BIOLOGICAL ACTIVITY

<b>Description</b>	Palmatine is an orally active and irreversible indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor with IC <sub>50</sub> s of 3 μM and 157 μM against HEK 293-hIDO-1 and rhIDO-1, respectively. Palmatine can also inhibit West Nile virus (WNV) NS2B-NS3 protease in an uncompetitive manner with an IC <sub>50</sub> of 96 μM. Palmatine shows anti-cancer, anti-oxidation, anti-inflammatory, neuroprotection, antibacterial, anti-viral activities <sup>[1][2][3][4][5]</sup> .																
<b>IC<sub>50</sub> &amp; Target</b>	IDO-1 3 μM (IC <sub>50</sub> , HEK 293-hIDO-1)	IDO-1 157 μM (IC <sub>50</sub> , rhIDO-1)	WNV NS2B-NS3 96 μM (IC <sub>50</sub> )														
<b>In Vitro</b>	<p>Palmatine (0-100 μM; 42 h) suppresses WNV with an EC<sub>50</sub> value of 3.6 μM, and reduce the viral titers of DENV-2 and YFV with EC<sub>50</sub> values of 26.4 μM and 7.3 μM, respectively<sup>[3]</sup>.</p> <p>Palmatine (0-1128 μM; 24-72 h) inhibits colon cancer cell proliferation<sup>[5]</sup>.</p> <p>Palmatine (0-704 μM; 24 h) reduces AURKA protein levels, induces G2/M phase arrest, and induces apoptosis in colon cancer cells via the mitochondrial associated pathway<sup>[5]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay<sup>[5]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HCT-116, SW480, HT-29</td> </tr> <tr> <td>Concentration:</td> <td>0, 88, 176, 352, and 704 μM (HCT-116, SW480); 0, 141, 282, 564, and 1128 μM (HT-29)</td> </tr> <tr> <td>Incubation Time:</td> <td>24, 48 and 72 h</td> </tr> <tr> <td>Result:</td> <td>Decreased cell viability in a dose-dependent manner.</td> </tr> </table> <p>Western Blot Analysis<sup>[5]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>HCT-116, SW480, HT-29</td> </tr> <tr> <td>Concentration:</td> <td>100 nM for HCT-116, 500 nM for SW480 and HT-29</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> </table>			Cell Line:	HCT-116, SW480, HT-29	Concentration:	0, 88, 176, 352, and 704 μM (HCT-116, SW480); 0, 141, 282, 564, and 1128 μM (HT-29)	Incubation Time:	24, 48 and 72 h	Result:	Decreased cell viability in a dose-dependent manner.	Cell Line:	HCT-116, SW480, HT-29	Concentration:	100 nM for HCT-116, 500 nM for SW480 and HT-29	Incubation Time:	24 h
Cell Line:	HCT-116, SW480, HT-29																
Concentration:	0, 88, 176, 352, and 704 μM (HCT-116, SW480); 0, 141, 282, 564, and 1128 μM (HT-29)																
Incubation Time:	24, 48 and 72 h																
Result:	Decreased cell viability in a dose-dependent manner.																
Cell Line:	HCT-116, SW480, HT-29																
Concentration:	100 nM for HCT-116, 500 nM for SW480 and HT-29																
Incubation Time:	24 h																

Result:	Promoted the expression of apoptosis markers such as P53 / P73, Caspase3, and Caspase9. Reduced AURKA protein levels. Increased cyt. c in the cytoplasm while reduced Bcl2 and Bcl-xl in a dose-dependent manner.
---------	---

#### Cell Cycle Analysis<sup>[5]</sup>

Cell Line:	HCT-116, SW480
Concentration:	88, 176, 352 and 704 $\mu$ M
Incubation Time:	24 h
Result:	Induced G2/M phase arrest in a dose-dependent manner.

#### Apoptosis Analysis<sup>[5]</sup>

Cell Line:	HCT-116, SW480
Concentration:	88, 176, 352 and 704 $\mu$ M
Incubation Time:	24 h
Result:	Induced apoptosis in a dose-dependent manner.

### In Vivo

Palmatine (50 or 100 mg/kg; p.o.; daily for 7 days) ameliorates DSS (dextran sulfate sodium)-induced colitis and prevents infiltration of inflammatory cells<sup>[1]</sup>.

Palmatine (0-200 mg/kg; i.p.; once) attenuates D-galactosamine/[Lipopolysaccharides](#) (HY-D1056)-induced fulminant hepatic failure in mice<sup>[2]</sup>.

Palmatine (0-1 mg/kg; i.p.; 10 days) shows memory-enhancing activity in mice<sup>[4]</sup>.

Palmatine (33.75-135 mg/kg; p.o.; daily for 26 days) can effectively inhibit the growth of HCT-116 xenografts in mice<sup>[5]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	DSS- induced Colitis BALB/c mice model (8-week-old) <sup>[1]</sup>
Dosage:	50 or 100 mg/kg
Administration:	Orally, daily, for 7 days
Result:	Ameliorated DSS-induced colitis and prevented infiltration of inflammatory cells; remarkably extended the colon length; significantly suppressed the colonic MPO activity. Decreased the levels of colonic inflammatory cytokines (TNF- $\alpha$ , IFN- $\gamma$ , IL-1 $\beta$ , IL-6, IL-4 and IL-10); Protected mucosal integrity by modulating TJ protein and apoptosis proteins; Restored DSS-induced decreases of TJ protein ZO-1, ZO-2 and claudin-1; Reduced Bax expression and enhanced Bcl-2 expression at the dose of 100 mg/kg, prevented epithelial apoptosis and improved intestinal integrity. Prevented DSS-induced changes of gut microbiota in colitis mice.

Animal Model:	Male ICR mice (20–22 g), D-galactosamine/lipopolysaccharide (GalN/LPS)-induced fulminant hepatic failure model <sup>[2]</sup>
Dosage:	25, 50, 100, or 200 mg/kg
Administration:	Intraperitoneal injection, 1 h before the GalN/LPS treatment

Result:	Attenuated the mortality and serum aminotransferase activities increased by GalN/LPS. Prevented the increase of serum TNF- $\alpha$ and augmented that of serum IL-10. Decreased the TNF- $\alpha$ mRNA expression and increased the IL-10 mRNA expression. Attenuated the apoptosis of hepatocytes.
Animal Model:	Swiss young male albino mice, with <a href="#">Scopolamine</a> (HY-N0296)- and diazepam-induced amnesia model <sup>[4]</sup>
Dosage:	0.1, 0.5, 1 mg/kg
Administration:	Intraperitoneal injection, 10 days
Result:	Significantly improved learning and memory of mice at 0.5 and 1 mg/kg and did not show any significant effect on locomotor activity of the mice. Significantly reversed scopolamine- and diazepam-induced amnesia in mice. Significantly reduced brain acetylcholinesterase activity of mice.
Animal Model:	BALB/c-nude mice, HCT-116 xenograft model <sup>[5]</sup>
Dosage:	33.75, 67.5 and 135 mg/kg
Administration:	Oral administration, once a day for 26 days
Result:	The tumor volume and weight of the treatment group were significantly reduced.

## CUSTOMER VALIDATION

- Biol Res. 2020 Sep 14;53(1):39.
- Int Immunopharmacol. 2022 Feb 9;106:108583.
- J Ethnopharmacol. 2023 Sep 27:117238.
- Molecules. 2024 May 14.
- Drug Dev Res. 2022 Aug 17.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

- [1]. Lee WC, et al. Palmatine attenuates D-galactosamine/lipopolysaccharide-induced fulminant hepatic failure in mice. Food Chem Toxicol. 2010 Jan;48(1):222-8.
- [2]. Jia F, et al. Identification of palmatine as an inhibitor of West Nile virus. Arch Virol. 2010 Aug;155(8):1325-9.
- [3]. Dhingra D, et al. Memory-enhancing activity of palmatine in mice using elevated plus maze and morris water maze. Adv Pharmacol Sci. 2012;2012:357368.
- [4]. Liu X, et al. Palmatine induces G2/M phase arrest and mitochondrial-associated pathway apoptosis in colon cancer cells by targeting AURKA. Biochem Pharmacol. 2020 May;175:113933.
- [5]. Long J, et al. Palmatine: A review of its pharmacology, toxicity and pharmacokinetics. Biochimie. 2019 Jul;162:176-184.
- [6]. Zhang XJ, et al. Palmatine ameliorated murine colitis by suppressing tryptophan metabolism and regulating gut microbiota. Pharmacol Res. 2018 Nov;137:34-46.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA